Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.
Michael Snyder, MD, FACS, FASMBS
Advertisement
Articles by Michael Snyder, MD, FACS, FASMBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
2
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
New Review Offers Framework for Sequencing Disease-Modifying Therapies in MS
5